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MR spectroscopy imagingAbstract Background: Using diffusion-weighted imaging (DWI) combined to MRI is helpful to
distinguish malignant versus benign breast lesions. Proton magnetic resonance spectroscopy pro-
vides biochemical information about the tissue under investigation.
Patient and methods: The study included 30 patients with suspicious breast lesions detected by clin-
ical examination, mammography and/or breast ultrasound. All patients included in this study were
subjected to Mammographic examination, ultrasound examination, and MRI examination includ-
ing diffusion-weighted imaging and proton MR spectroscopy.
Results: In this study the sensitivity of MRS was 90%, its speciﬁcity was 78.6%, accuracy was
85%, PPV was 85.7% and NPV was 84.6%. Regarding the sensitivity of diffusion and apparent
diffusion coefﬁcient (ADC), it was 90%, while its speciﬁcity was 92.8% and 91.1%, 94.7%,
86.6% for the accuracy, PPV and NPV respectively.
Conclusion: The combination of MRS and DWI with magnetic resonance imaging should provide
complementary information not available by either modality alone.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is now a signiﬁcant cause of worldwide morbid-
ity and mortality. Further, the increasing rate of breast cancer
continues to be a major area of concern for both clinicians andresearchers. Increased awareness in the affected population
leads to more frequent physical examinations and diagnostic
imaging procedures which results in earlier diagnosis and
hence improved prognosis (1).
The majority of the lesions that occur in the breast are
benign. It is important to recognize benign lesions and distin-
guish them from breast cancer (2).
Breast MRI may be used to distinguish between benign and
malignant areas, reducing the number of breast biopsies done
to evaluate a suspicious breast mass. Although MRI can detect
tumors in dense breast tissue, it cannot detect tiny specks of
calcium (known as microcalciﬁcations), which account for half
of the cancers detected by mammography (3).
Fig. 1 A 29 year old female patient: (A) Axial T1WI shows a large well-deﬁned hypointense cystic lesion seen at right upper outer
quadrant with smooth margin. (B) DWI at b= 1000 shows low signal mass denoting facilitated diffusion. (C) Apparent ADC map reveals
hyperintense mass (the mean ADC value of the cystic lesion = 1.82  103 mm2/s). (D) MRS of the lesion reveals broad choline peak. The
lesion histopathologically proved as infected cystic lesion.
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combined to MRI enhances such differentiation between
malignant and benign breast lesions (4).
Magnetic resonance (MR) spectroscopy is providing bio-
chemical information about the tissue under investigation
(5). Several studies over the past decade documented that
Cho is speciﬁc to malignancy and can be used to differentiate
cancerous from benign tissues (6).
The aims of this work were to assess the role of
diffusion-weighted imaging and proton magnetic resonance
spectroscopy in evaluation of breast masses and comparing
the results with histopathology.2. Patient and methods
The current study is cross sectional study included 30 patients
with suspicious breast lesions detected by clinical examination,
mammography and/or breast ultrasound; their mean age was
42 years (±10.4) (age range, 19–65 years). They were referred
to Radiology Department, Zagazig University Hospitals from
General Surgery and Oncology Departments.
All patients were subjected to the following:
(1): Full clinical history:
 Personal history, including the age, occupation and
residency.
 Past history, including history of breast pain, lump, breast
surgery as well as history of any procedure which might
interfere with the MRI examination (e.g. cardiac pacemaker
placement or cerebral aneurysm surgery).
(2): Physical examination:
Breast examination focused on palpable lumps, skinthickening, nipple retraction and examination of the
axilla for any palpable enlarged nodes.(3): Mammographic examination
Digital mammography was reviewed (mediolateral obli-
que and craniocaudal views). Mammographic images
were evaluated as regards the presence or absence of
suspicious lesion.
(4): Ultrasound examination:
Ultrasound was reviewed for the presence or absence of
breast masses.(5): MRI examination:
MRI was done in Zagazig University Hospital using
Philips Achieva 1.5T scanner with a dedicated breast
coil.
Before the examination, the patient’s consents were taken
and patients were informed about the duration of the examina-
tion and the importance of remaining still during image acqui-
sition. The patient lies prone on the examination couch with
her breasts in the dedicated breast coil; the patient’s arms
are positioned beside her head. Her head is supported with a
head holder and a pillow is placed under her legs to make
her tolerate the prone position.
2.1. Sequences
The study starts with a three plane localizer then with axial
T1WI [TR, msec 450 and TE, msec 1], T2WI [TR, msec4000 and TE 120, msec 10) and fat saturated T2WI or T1WI
which were obtained with slice thickness of 3 mm and 1 mm
interslice gap. FOV was set at 360 mm. The following param-
eters were used.
2.2. MRI interpretation
MRI images were reviewed and evaluated for Lesional number
and site of lesions, shape (round, oval, lobulated, irregular),
margins (smooth, spiculated, irregular), and signal intensity
in T1WI and T2WI. Nature of the lesion (cystic or solid),
and presence of signal voids or internal septations. Skin thick-
ening, nipple retraction, pectoralis major invasion and pres-
ence of enlarged axillary lymph nodes.
2.3. Diffusion-weighted imaging
DWI was performed using Philips Achieva 1.5T scanner;
reduction factor 2, 7000/71.5 number of excitations 2; matrix
240  240 ﬁeld of view, 34 cm; slice thickness, 3 mm, 0, b fac-
tor = (0 and 1000 s/mm2), and the scanning time was 4 min.
Respiratory triggering was used for better resolution. The
ADC value is a quantitative measurement of diffusion that is
calculated on the basis of the attenuation in signal intensity
between at least two diffusion-weighted images according to
the following equation:
ADC value ¼ InðSDW=SSEÞ=b;
where SDW is the attenuated spin-echo signal and is the full
spin-echo signal without diffusion attenuation and b value
(expressed in seconds per square millimeter) represents the
strength of diffusion weighting
The apparent diffusion coefﬁcient (ADC) values were
automatically calculated by placing the ROI well within the
conﬁnes of the lesion. Fatty glandular parenchyma, which
shows homogeneous signal intensity on the ADC map, was
used as a reference. The scanner software provides the mean
value within the ROI, which equals the ADC value (multiplied
by 103). Diffusion weighted images and ADC maps are then
examined regarding the signal intensity and the mean ADC of
each lesion.2.4. Proton MR spectroscopy
Before MR spectroscopy, local homogeneity of the ﬁeld is ver-
iﬁed by shimming. Also effectiveness of fat and water suppres-
sion is checked. PRESS sequence is then performed (TR/TE
1500/136 ms; bandwidth 1 kHz; 512 excitations); single Voxel
is placed upon the suspicious area. The sequence includes three
successive selective pulses positioned in the three orthogonal
planes and intersecting in the Voxel we want to study. The
acquisition time was about 10 min. Postprocessing of the
acquired data is then performed and includes different signal
ﬁlters, frequency correction, phase correction, baseline correc-
tion and curve ﬁtting to optimize the spectral proﬁle. Choline
peak is at 3.2 ppm.
MRS was analyzed according to the presence or absence of
choline peak in the spectrum, and whether the peak – if present –
is tall or broad.
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 Broad peak was interpreted as benign.
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(6): Histopathological correlation:
From the 34 evaluated lesions 20 lesions were resectedFig. 2
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mean
histopasurgically whereas patients with the other lesions
underwent ultrasound guided biopsy, 9 with FNAB
and 5 with core biopsy. The histopathological diagnosis
was obtained in all lesions and was the standard of
reference.(7): Data analysis:
Data were statistically described in terms of frequencies
(number of cases) and percentages when appropriate.
Accuracy was represented using the terms sensitivity,
speciﬁcity, positive predictive value, negative predictive
value, and overall accuracy.3. Result
This study included 30 female patients with 34 breast
lesions, their ages ranged from 19 to 65 years with a mean of
42.24 ± 10.6 years. As regards the age distribution of the
patients the most common age is 50–60 years. The age of
patients is younger in cases with benign lesions, and
10 patients had previous breast surgery. Conventional MRI,
diffusion-weighted images and MRI spectroscopy were per-
formed to all patients after taking their consent. Previous
ultrasound and mammography were reviewed if present.
Histopathological diagnosis was performed in all patients (sur-A 33 year old female patient: (A) Axial T1WI shows small fa
uadrant with well-deﬁned margins. (B) Apparent ADC map reve
ADC value of the cystic lesion = 1.42  103 mm2/s). (C)
thologically proved as ﬁbroadenoma.gical specimen in 20 lesions, FNAB in 9 lesions and core
biopsy in 5 lesions).
As regards the patient complaint, 58.8% of patients com-
plain of painless lump, 20.5% complain of painful lump,
32.3% show skin thickening and nipple retraction, 8.8% com-
plain of pain and 29.4% came for follow-up. Ten cases
(33.3%) had positive family history while twenty cases
(66.7%) had negative family history (see Figs. 1–4 and Tables
1–8).
4. Discussion
Screening for breast cancer has been shown to decrease mor-
tality, and mammography is the main screening tool; ultra-
sound and magnetic resonance imaging have been used as
adjunctive tools, mainly for women who may be at increased
risk for the development of breast cancer (7,8).
In our study histopathological diagnosis of benign lesions
(14 cases) included 50% ﬁbroadenomas, 14.3% papillomas,
14.3% infected cystic lesions, 14.3% ﬁbrocystic and 7.1%
radial scars (9), reported that ﬁbroadenoma is the most com-
mon benign breast mass comprising about 88% of benign
masses.
On the other hand, the histopathologic diagnosis of malig-
nant lesions (20 cases) in this study included 60% invasive ductal
carcinomas, 25% invasive lobular carcinomas, 5% medullary
carcinomas , 5% inﬂammatory carcinoma and 5% mucinous
carcinomas. Our results coincide with (10) which reported inva-
sive ductal carcinoma is the most common malignant breast
mass comprising about 73% of malignant masses.irly deﬁned hypointense breast mass (yellow arrow) at left upper
als hyperintense mass (yellow arrow) with facilitated diffusion (the
MRS of the lesion reveals absent choline peak. The lesion
Fig. 3 A 63 year old female patient: (A) Axial T1WI shows right upper central ill-deﬁned hypointense breast mass with speculated
margins. (B) DWI at b= 1000 shows bright signal of the mass (yellow arrow) denoting restriction. (C) Apparent ADC map reveals
hypointense mass (yellow arrow) (the mean ADC value of the cystic lesion = 0.79  103 mm2/s). (D) MRS of the lesion reveals tall
choline peak. The lesion histopathologically proved as invasive lobular carcinoma.
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margin or smooth shape/margin (80–82%) while the features
with highest positive predictive value for carcinoma were spec-ulated margin in 100% and irregular shape in 97% (11). Also
(12), reported that 14% of malignant lesions are round, oval or
lobulated and 86% are irregular in shape.
Fig. 4 A 47 year old female patient: (A) Axial T1WI shows left upper outer quadrant breast ill-deﬁned hypointense mass with irregular
margin. (B) DWI at b= 1000 shows bright signal of the mass denoting restriction. (C) Apparent ADC map reveals hypointense mass
(yellow arrow) (the mean ADC value of the cystic lesion = 0.90  103 mm2/s). (D) MRS of the lesion reveals tall choline peak. The lesion
histopathologically proved as invasive ductal carcinoma.
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hypointense in T1WI while in T2WI, 64.3% of benign lesions
are iso to hypointense and 35.7% are hyperintense, 90%
of malignant lesions are iso to hypointense and 10% arehyperintense in T2WI. Low T2 internal septations are detected
in 2 (15.4%) benign lesions and none of malignant lesions.
This is in agreement with (13) who stated that T2 signal
intensity was not a signiﬁcant predictor of malignancy and
Table 1 Anatomical distribution of lesions, and distribution
of the detected breast lesions in correlation with histopatho-
logical results.
Quadrant Count % Benign (no.
= 14)
Malignant (no.
= 20)
UOQ 15 44.1 5 10
LOQ 6 17.6 3 3
LIQ 5 14.7 3 2
UIO 4 11.8 2 2
Retro-areolar 2 5.9 0 2
More > one
quadrant
2 5.9 1 1
Regarding 14 benign lesions, 7 (50%) were ﬁbroadenomas, 2
(14.2%) papillomas, 2 (14%) abscess, 2 (14.2%) ﬁbrocystic diseases
and 1 (7.1%) radial scar, whereas regarding 20 malignant lesions 12
(60%) were invasive ductal carcinomas and 5 (25%) were invasive
lobular carcinomas, 1 (5%) medullary carcinoma, 1 (5%) inﬂam-
matory carcinoma and 1 (5%) radial scar.
Table 2 Evaluation by non-contrast MR imaging of the
patients.
Noncontrast MR criteria Benign (no.
= 14)
Malignant (no.
= 20)
No. % No. %
Shape
Rounded 5 35.7 2 10
Oval 4 28.5 2 10
Irregular 2 14.2 10 50
Lobulated 3 21.4 6 30
Border
Well deﬁned 11 78.6 2 10
Speculated – – 10 50
Ill-deﬁned 3 21.4 8 40
T1 signal
Iso to low 14 100 20 100
High – – – –
T2 signal
Iso to low 9 64.3 18 90
High 5 35.7 2 10
Low T2 internal septations
Present 2 15.4 – –
Absent 12 85.7 20 100
Assessment of breast mass 1333all masses in their study with internal septa were ﬁbroadeno-
mas. However (14) stated that internal septations, a descrip-
tion usually associated with ﬁbroadenomas, are a sign that is
no longer exclusive to benign lesions. In their study which
included 55 lesions, one lesion with internal septa proved to
be well differentiated invasive ductal carcinoma.
Complementary MR techniques have emerged as MRI
investigates anatomic changes associated with neoplastic
disease, while 1H MRS is able to examine the biochemistry
of tissue and to detect spatial deviations from normal
biochemistry in neoplastic tissues (7).
The goal of obtaining non-invasive biopsy information
through the use of such methodology has pushed the develop-
ment of several optimized localized MRS procedures as
a unique means to probe the biochemistry of living systems
with diagnostic importance by its ability to measure
endogenous metabolites non-invasively as well as changes in
tissue metabolism (15).
Unlike for the brain and prostate, breast spectra typically
exhibit only a single metabolite peak located at approximately
3.2 ppm, which is elevated in cancer in comparison with nor-
mal breast tissues (16). 1H MRS is not a method for detecting
breast lesions but rather a method for their characterization.
As choline containing compounds are believed to be precur-
sors of the phospholipids that compose cell membranes,
increases in Cho signals are thought to reﬂect increased mem-
brane cellular synthesis associated with malignancy (9).
MRS of the breast, has shown that choline-containing com-
pounds can be detected in most breast cancers (17), whereas
choline is generally not detectable in normal breast tissues.
Thus MR spectroscopy can be helpful in diagnosis of indeter-
minate lesions based on the well-established principle that
malignant tissues show elevated concentrations of choline, a
product of membrane synthesis, so elevated choline is consid-
ered as marker for cancer (18).
In our study, 78.6% of benign lesions showed no or broad
choline peak whereas tall choline peak was detected in 21.4%
of lesions. On the other hand, 90% of malignant lesions
showed tall choline peak and 10% had no or broad choline
peak.
Based upon absence of choline, 11 benign lesions were diag-
nosed correctly; yet, choline peak was observed in 3 benign
lesions (3 were false positive, 2 were ﬁbroadenomas and the
third was intraductal papilloma). As regards malignant lesions,
18 were correctly diagnosed on the basis of choline peak and 2
showed absent choline (2 false negative intraductal carcino-
mas). Sensitivity of MRS was 90.8%, its speciﬁcity was
78.6%, and accuracy was 85%. PPV was 85.7% and NPV
was 84.6%.
Our results were in agreement with (19), who reported the
overall combined sensitivity and speciﬁcity of MRS as 83%
and 85%, respectively and also with (18), who reported that
the sensitivity and speciﬁcity were 93.6% (88/94) and 77.9%
(152/195), respectively; however (17) reported sensitivity of
100%, and speciﬁcity of 88%. The major limiting factor that
affects sensitivity was the small size of the tumor and this
agrees with this feature which was noted by (18), who found
decreasing diagnostic sensitivity of choline detection with
smaller lesion sizes. (19), who included small lesions in their
diagnostic study, reported a diagnostic sensitivity of 82% in
lesions larger than 15 mm in maximum length, but only 42%
when considering all lesions.In our study false positive choline peak was detected in 3
benign lesions. This ﬁnding was in agreement with (18), who
reported that seven false positive cases were encountered.
The histologic diagnoses in the seven false-positive mass
lesions by MRS included were ﬁbroadenomas and three of
these were found in lactating females. In these cases the peak
of choline was characteristically short and biﬁd and also
(20), reported that most studies have reported some false pos-
itives with no speciﬁc benign pathology implicated.
In our study, false negative results were observed in 2
malignant lesions (2 false negative intraductal carcinomas) in
agreement with (18) and explained by the lesional necrosis.
Table 3 Signs associated with benign and malignant lesions.
Associated signs Benign Malignant
Skin thickening
Present 1 7.1% 15 75%
Absent 13 92.9% 5 25%
Nipple retraction
Present – – 15 75%
Absent 14 100% 5 25%
Axillary lymphadenopathy
Present 4 28.6% 12 60%
Absent 10 71.4% 8 40%
N.B: One patient had more than one ﬁnding.
MRS evaluation: Regarding choline peak in our study, 8 cases
(23.5%) had no choline peak, 5 (14.7%) had broad peak while 21
(61.8%) had tall peak. The tall peak only is considered a marker for
malignancy. No and broad choline peaks are considered benign.
Table 4 Presence of choline peak in the detected lesions.
Choline peak Benign Malignant
No. % No. %
Present (tall peak) 3 21.4 18 90
Absent (broad or no peak) 11 78.6 2 10
The diffusion criteria were assessed for breast lesions as restricted
or facilitated. 92.9% of benign lesions showed facilitated diffusion
while 7.1% of benign lesions showed restricted diffusion while 90%
of malignant lesions showed restricted diffusion and 10% of
malignant lesions showed facilitated diffusion.
Table 5 The characters of lesions on DW images in relation to
the histopathology.
Diﬀusion Benign Malignant
Restricted 1 (7.1%) 18 (90%)
Facilitated 13 (92.9%) 2 (10%)
Total 14 20
Table 6 The minimum, maximum and mean of the ADC
values ( 103 mm2/s) in benign and malignant mass lesions.
Pathology Minimum Maximum Mean
Benign 0.9 2.12 1.54
Malignant 0.56 1.4 0.86
Table 7 Comparison between MRI ﬁndings, diffusion and
MRS.
Correct
diagnosis
False
+ve
False
ve
Total
MRI
ﬁndings
Benign 9 5 – 14
Malignant 16 – 4 20
MRS Benign 11 3 – 14
Malignant 18 – 2 20
Diﬀusion
and ADC
Benign 13 1 – 14
Malignant 18 – 2 20
MRI ﬁndings, MRS and DWI correct diagnosis, false positive and
false negative ﬁnding reported in Table 7.
Table 8 Sensitivity, speciﬁcity, accuracy, positive predictive
value (PPV) and negative predictive value (NPV) of MRI
diagnosis, diffusion and MRS.
Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
(%)
PPV
(%)
NPV
(%)
MRI
diagnosis
80 64.3 73.5 76.2 69.2
MRS 90 78.6 85 85.7 84.6
Diﬀusion
and ADC
90 92.8 91.1 94.7 86.6
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tial of DWI to differentiate between benign and malignant
breast masses, excellent detection, and location of the breast
cancer is supposed to be possible without the use of a contrast
agent, in spite of the signiﬁcant geometrical distortion on DWI
(21,22).
Hence, DWI is a promising tool in screening for breast can-
cer without using contrast medium. Investigations on DWI ofthe breast so far mainly focused on ADC measurements in
order to differentiate between benign and malignant lesions.
SMD analysis of reported mean ADC values indicates major
diffusivity differences between benign and malignant lesions.
This fact is reﬂected in the reported high sensitivity and speci-
ﬁcity values (23,24).
In our study 92.9% of benign lesions showed facilitated
diffusion while 7.1% of benign lesions showed restricted diffu-
sion, 90% of malignant lesions showed restricted diffusion and
10% of malignant lesions showed facilitated diffusion sensitiv-
ity of diffusion; ADC was 90%, its speciﬁcity was 92.8%, accu-
racy was 91.1%, PPV was 94.7% and NPV was 86.6%. Our
DWI results show lower ADC value of the malignant lesions.
This was in agreement with (25) who reported that low value is
due to increased cellularity of the densely packed randomly
organized tumor cells, with (26) who reported the sensitivity
and speciﬁcity as high as 92% and 96%, respectively and with
(27), who reported that ADC values for the detection of malig-
nant lesions showed a sensitivity of 97.22% and a speciﬁcity of
100%; however (28) reported a speciﬁcity of 67% (43/64) and a
sensitivity of 97% (61/63) for mass and focal lesions, regardless
of lesion size.
The single false positive case found in this study was diag-
nosed as malignant according to its morphologic and plain
MRI picture and the two false negative cases were diagnosed
as benign and found to be mucinous and medullary carcinoma.
This agrees with (29) who suggest it is due to lower cell density
and higher extracellular water content and the high cellularity
in cases such as the papilloma seen in our study, and resulted
in misleading ADC values.
Assessment of breast mass 13355. Conclusion
Both DWI and MRS are useful diagnostic modalities for char-
acterization and differentiation between benign and malignant
breast lumps. Our preliminary results showed that combina-
tion of DWI and calculated ADC values and metabolite spec-
trum acquired by MRS add more information to MRI and
should be considered as an additional and complementary tool
to conventional MRI for differentiating benign from malig-
nant masses.
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